Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | ADK | P55263 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21441054 | 0.88 | HDAC6 (0.57) | APPHSD17B1HSD17B2ERN1CA1 | |
| SCHEMBL20417352 | 0.86 | APP (0.41) | APPHSD17B1HSD17B2ERN1CA1 | |
| SCHEMBL22363333 | 0.85 | APP (0.40) | APPHSD17B1HSD17B2ERN1CA1 | |
| SCHEMBL19217080 | 0.81 | ALOX5 (0.42) | APPCA1CA2CA9HDAC6 | |
| SCHEMBL19346119 | 0.80 | HDAC6 (0.43) | APPCA1CA2CA9HDAC6 | |
| SCHEMBL16720164 | 0.80 | HDAC6 (0.42) | APPHSD17B1HSD17B2HDAC6AHR | |
| SCHEMBL28813263 | 0.79 | APP (0.67) | APPHSD17B1HSD17B2ERN1CA1 | |
| SCHEMBL20920740 | 0.79 | HDAC6 (0.39) | HSD17B1HSD17B2HDAC6AHRBRD4 | |
| SCHEMBL5384482 | 0.78 | APP (0.65) | APPHSD17B1HSD17B2ERN1CA1 | |
| SCHEMBL24177393 | 0.77 | HDAC6 (0.48) | APPHSD17B1HSD17B2HDAC6AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-02-23 | — | — | US | disclosed |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223834-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2020-07-16 | — | — | US | disclosed |
| US-7772256-B2 | 2-heteroaryl substituted benzothiophenes and benzofuranes 709 | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-7772256-B2 | 2-heteroaryl substituted benzothiophenes and benzofuranes 709 | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20080221149-A1 | 2-[6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol; for imaging amyloid deposits in living patients | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221149-A1 | 2-[6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol; for imaging amyloid deposits in living patients | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223834-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | APP 38/4885HSD17B1 135/4885HSD17B2 137/4885 |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, PKD1, ACE2 | APP 4041/4885HSD17B1 106/4885HSD17B2 350/4885 |
| US-20080221149-A1 | 2-[6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol; for imaging amyloid deposits in living patients | PSEN1, APP, PSEN2 | APP 2/4885HSD17B1 1842/4885HSD17B2 2205/4885 |
| US-20230053726-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | APP 38/4885HSD17B1 135/4885HSD17B2 137/4885 |
| US-11034682-B2 | Gamma-diketones as wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | APP 40/4885HSD17B1 137/4885HSD17B2 139/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | APP 36/4885HSD17B1 135/4885HSD17B2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.